Publication:
The current status of COVID-19 vaccines. A scoping review.

Simple item page
dc.contributor.authorRueda-Fernandez, Manuel
dc.contributor.authorMelguizo-Rodriguez, Lucia
dc.contributor.authorCostela-Ruiz, Victor J
dc.contributor.authorGonzalez-Acedo, Anabel
dc.contributor.authorRamos-Torrecillas, Javier
dc.contributor.authorIllescas-Montes, Rebeca
dc.contributor.funderResearch group BIO277 (Junta de Andalucía)
dc.contributor.funderDepartment of Nursing (University of Granada)
dc.date.accessioned2023-05-03T14:54:35Z
dc.date.available2023-05-03T14:54:35Z
dc.date.issued2022-08-19
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new disease that has led to a worldwide pandemic, resulting in millions of deaths and a high economic burden. Here, we analyze the current status of preventive vaccines authorized by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Published clinical trials have shown the effectiveness of mRNA (BNT162b2 and Spikevax), adenovirus vector-based (Ad26.COV2.S and ChAdOx1 nCoV-19), and recombinant protein S (NVX-CoV2373) vaccines to be between 52.9% and 100%. The most-frequent adverse effects include local pain, fatigue, headache, or chills. Serious events are associated with Ad26.COV2.S and ChAdOx1 nCoV-19 vaccines.
dc.identifier.citationRueda-Fernández M, Melguizo-Rodríguez L, Costela-Ruiz VJ, González-Acedo A, Ramos-Torrecillas J, Illescas-Montes R. The current status of COVID-19 vaccines. A scoping review. Drug Discov Today. 2022 Nov;27(11):103336.
dc.identifier.doi10.1016/j.drudis.2022.08.004
dc.identifier.essn1878-5832
dc.identifier.pmcPMC9389839
dc.identifier.pmid35995361
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389839/pdf
dc.identifier.unpaywallURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389839
dc.identifier.urihttp://hdl.handle.net/10668/22156
dc.issue.number11
dc.journal.titleDrug discovery today
dc.journal.titleabbreviationDrug Discov Today
dc.language.isoen
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.page.number12
dc.provenanceRealizada la curación de contenido 09/08/2024
dc.publisherElsevier Ltd. * Trends Journals
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S1359-6446(22)00306-3
dc.rights.accessRightsRestricted Access
dc.subjectHumans
dc.subjectNVX-CoV2373 adjuvated lipid nanoparticle
dc.subjectChAdOx1 nCoV-19
dc.subjectSARS-CoV-2
dc.subject.decsAdenoviridae
dc.subject.decsCefalea
dc.subject.decsEnfermedad iatrogénica
dc.subject.decsEstrés financiero
dc.subject.decsPan
dc.subject.decsPandemias
dc.subject.decsAdministration
dc.subject.decsVacuna BNT162
dc.subject.decsVacuna nCoV-2019 mRNA-1273
dc.subject.decsVacunas sintéticas
dc.subject.meshBNT162 Vaccine
dc.subject.meshAd26COVS1
dc.subject.mesh2019-nCoV Vaccine mRNA-1273
dc.subject.meshFinancial Stress
dc.subject.meshPandemics
dc.subject.meshUnited States Food and Drug Administration
dc.subject.meshVaccines, Synthetic
dc.subject.meshIatrogenic Disease
dc.subject.meshHeadache
dc.subject.meshPain
dc.subject.meshAdenoviridae
dc.titleThe current status of COVID-19 vaccines. A scoping review.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number27
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

Instituto de Investigación Biosanitaria de Granada (ibsGRANADA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía